Evidence map›Paper›PMID 31615000›Full record

ArticlePathogens (Basel, Switzerland)2019

Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing.

Johan H Melendez, Yu-Hsiang Hsieh, Mathilda Barnes, Justin Hardick, Elizabeth A Gilliams, Charlotte A Gaydos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Local emergence and global evolution ofAntimicrobial agents and chemotherapy · 2024
    Article
  2. Article
  3. Pathogens (Basel, Switzerland) · 2020
    Article
  4. Point-by-Point Progress: Gonorrhea Point of Care Tests.Expert review of molecular diagnostics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Johan H MelendezDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. jmelend3@jhmi.edu.
Yu-Hsiang HsiehDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD 21205, USA. yhsieh1@jhmi.edu.
Mathilda BarnesDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. mbarnes2@jhmi.edu.
Justin HardickDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. jhardic1@jhmi.edu.
Elizabeth A GilliamsJohns Hopkins School of Medicine, Baltimore, MD 21205, USA. Elizabeth.Gilliams@baltimorecity.gov.
Charlotte A GaydosDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. cgaydos@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
NIAID NIH HHS UM1 AI068613NIH HHS NIBIB 1U54 EB007958, NIAID U-01068613
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antimicrobial resistanceciprofloxacin resistancegonorrheaNeisseria gonorrhoeaeprecision treatment

Identifiers

PMID31615000
PMCPMC6963864
OpenAlexW2980070504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.